Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01731990 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT01731990 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 38 participants.
The verdict
NCT01731990, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
This study was designed to assess the safety, tolerability and efficacy of ACZ885 on the leg artery structure and physical activity in patients with atherosclerotic peripheral artery disease and leg pain from walking.
Interventions
- DRUG Placebo
- DRUG Canakinumab (ACZ885)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2012-10-30 |
| Est. Completion | 2016-08-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01731990
The ClinicalTrials.gov registry entry for NCT01731990 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01731990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01731990 about?
NCT01731990 is a clinical study titled "Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease". This study was designed to assess the safety, tolerability and efficacy of ACZ885 on the leg artery structure and physical activity in patients with atherosclerotic peripheral artery disease and leg pain from walking.
What is the current status of trial NCT01731990?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2012-10-30. Estimated completion is 2016-08-04.
What interventions are being tested in trial NCT01731990?
The interventions under investigation include: Placebo (DRUG), Canakinumab (ACZ885) (DRUG).
Who is sponsoring clinical trial NCT01731990?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.